SEC For	m 4																
FORM 4 UN				STAT	ES S			ES AND		NGE C	OMMI	SSION		OMB	APPRO	/AL	
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See					NT OF CHANGES IN BENEFICIAL OWNERSHIP									OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
Instruc	tion 1(b).			Filed	pursuan or Sec	t to Section tion 30(h) o	n 16(a of the	a) of the Secu Investment C	rities Exchar Company Act	nge Act of 1 of 1940	934						
1. Name and Address of Reporting Person [*] <u>Kanter Stacy J.</u>					2. Issuer Name and Ticker or Trading Symbol <u>Applied Therapeutics Inc.</u> [APLT]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O APPLIED THERAPEUTICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 06/03/2022							Officer (give title Other (specify below) below)					
545 FIFTH AVENUE, SUITE 1400					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	(Street) NEW YORK NY 10017												X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip)																	
		Tab	ole I - Non-	Derivat	tive Se	ecurities	s Ac	quired, D	isposed o	of, or Be	neficial	ly Owned					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						2A. Deem Execution if any (Month/Da	Date	Code (Ins	on Dispose			4 and Securities Beneficial Owned Fo		Form (D) o	r Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code V	Amount	(A) or (D)	Price	Price Reported Transaction (Instr. 3 and					
		-	Table II - D (e					uired, Dis s, options				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da	ate, 4. Co	nsaction de (Instr.	5. Numl	ber ive ies ed ed nstr.	6. Date Exercisable ar Expiration Date (Month/Day/Year)		7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Co	de V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$1.22	06/03/2022		А		16,500		(1)	06/02/2032	Common Stock	16,500	\$0.00	16,50)0	D		

Explanation of Responses:

1. Consists of Options granted to directors under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. One-twelfth (1/12th) of the shares subject to the Option shall vest on July 2, 2022 and each month thereafter, subject to the Reporting Person continuing to provide services through each such date.

Remarks:

/s/ Shoshana Shendelman, as attorney-in-fact

06/07/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.